Stryker Co. (NYSE:SYK) Stock Position Boosted by BTG Pactual Asset Management US LLC

BTG Pactual Asset Management US LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 18.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,535 shares of the medical technology company's stock after acquiring an additional 877 shares during the period. BTG Pactual Asset Management US LLC's holdings in Stryker were worth $1,993,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of SYK. J. W. Coons Advisors LLC raised its stake in Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after buying an additional 26 shares during the last quarter. Mascoma Wealth Management LLC raised its position in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after acquiring an additional 27 shares during the period. Opal Wealth Advisors LLC boosted its stake in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after acquiring an additional 28 shares during the last quarter. Lindbrook Capital LLC grew its position in shares of Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after acquiring an additional 28 shares during the period. Finally, Alhambra Investment Management LLC lifted its position in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Remove Ads

Stryker Stock Down 1.9 %

Shares of Stryker stock traded down $6.54 during trading hours on Tuesday, reaching $346.88. 1,670,378 shares of the company were exchanged, compared to its average volume of 1,361,570. The stock's fifty day moving average is $373.64 and its 200 day moving average is $373.40. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market cap of $132.40 billion, a PE ratio of 44.70, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company earned $3.46 earnings per share. As a group, equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is currently 43.30%.

Analysts Set New Price Targets

SYK has been the subject of a number of recent analyst reports. Citigroup reiterated a "buy" rating and issued a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. StockNews.com downgraded shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Finally, Royal Bank of Canada lifted their price target on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $423.05.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.